Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

Not Applicable

Withdrawn

Brief Summary: The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal. The investigators will assess patient compliance and satisfaction with eVisit follow up care in lieu of in person clinic visits.

Detailed Description: Telehealth offers the opportunity to transform cancer surveillance into a patient-centered effort with shared leadership between patient and oncologist. Peer-to-peer electronic communications can improve the collaboration between oncologist and primary care provider (PCP) as patients transition back to primary care as their primary health provider. The investigators propose to test a patient-centered eHealth surveillance program utilizing novel asynchronous telehealth tools to provide patient-reported outcome symptom monitoring using the electronic medical record's patient portal (eVisit).

Recruitment & Eligibility

Inclusion Criteria

≥ 18 years old with histologically confirmed prostate cancer
Completed curative intent treatment to the prostate +/- pelvis
Deemed to be "without evidence of active disease" by treating provider with at least 1 follow up visit 3 or more months after treatment completion
MyChart account or willingness to open account
Access to the internet

Exclusion Criteria

Documented extrapelvic metastases
PSA meeting definition of recurrence (>0.2 ng/ml for prostatectomy patients or nadir + 2 ng/ml for radiation patients) and rising with doubling time less than 1 year

Arm && Interventions

Group	Intervention	Description
eVisit	eVisit	The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.

Primary Outcome Measures

Name	Time	Method
Proportion of patients who complete all scheduled eVisits at the end of follow-up	12 months	Defined as completion of labwork and at least 80% of the questions asked at each eVisit

Secondary Outcome Measures

Name	Time	Method
Number of eVisit participants with cancer recurrence	12 months	Defined as biochemical progression (PSA \>0.2 ng/ml for prostatectomy patients or nadir + 2 ng/ml for radiation patients) or metastasis (by imaging)
Financial impact of the eVisit program on participants compared to in person follow up clinic visits	12 months	Defined by the financial burden assessment completed by participants, scored from "0/not at all" through "4/very much"
Financial impact of the eVisit program on Duke University Hospital (institution) compared to in person follow up	12 months	Defined by qualitative analysis of reimbursement process
Feasibility of enrollment to the eVisit program	12 months	Defined as the percentage of patients who are approached for eVisit and ultimately enroll
eVisit participant reported satisfaction	12 months	Reported as the summary score from validated Brief Patient Satisfaction 10-item scale instrument assessed from "1/strongly agree" through "5/strongly disagree"
Number of participants with cancer treatment related toxicities	12 months	Defined specifically as CTCAE Grade 2 or higher GI, GU, hormonal, and sexual toxicities

Locations (4): Duke Raleigh Hospital
🇺🇸
Raleigh, North Carolina, United States
Duke Cancer Institute Cary
🇺🇸
Cary, North Carolina, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Durham Regional Hospital
🇺🇸
Durham, North Carolina, United States